Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Erlotinib/gemcitabine

Erlotinib/gemcitabine Reactions 1704, p153 - 2 Jun 2018 Various toxicities: 4 case reports In a retrospective study of 24 patients, four patients [ages and sexes not stated] were described who developed haematological toxicity, ulcer, gastric haemorrhage or duodenal stenosis following treatment with gemcitabine and erlotinib [routes, durations of treatments to reactions onsets and outcomes not stated] for locally advanced pancreatic cancer. The patients with unresectable locally advanced pancreatic cancer started receiving chemoradiotherapy (CRT) with gemcitabine 1000 mg/m on days 1, 8 and 15 and erlotinib 100 mg daily on a 4 week cycle, along with radiotherapy. The patients experienced grade 3 haematological toxicity, grade 2 ulcer, grade 3 gastric haemorrhage and grade 3 duodenal stenosis (one patient each). Author comment: "Grade 3 hematologic toxicity was observed in . . . 1 patient during CRT." "[G]rade 2 ulcer developed in 1 patient". "Grade 3 gastric hemorrhage was observed in 1 patient who received 50.4 Gy and grade 3 duodenal stenosis in 1 patient who received 55.8 Gy." Kim E, et al. Chemoradiotherapy after gemcitabine plus erlotinib in patients with locally advanced pancreatic cancer. Journal of B. U. ON: Official Journal of the Balkan Union of Oncology 22: 1046-1052, No. 4, Jul-Aug http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Erlotinib/gemcitabine

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018

Erlotinib/gemcitabine

Abstract

Reactions 1704, p153 - 2 Jun 2018 Various toxicities: 4 case reports In a retrospective study of 24 patients, four patients [ages and sexes not stated] were described who developed haematological toxicity, ulcer, gastric haemorrhage or duodenal stenosis following treatment with gemcitabine and erlotinib [routes, durations of treatments to reactions onsets and outcomes not stated] for locally advanced pancreatic cancer. The patients with unresectable locally advanced pancreatic cancer started...
Loading next page...
 
/lp/springer_journal/erlotinib-gemcitabine-UksRofCPmH

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46796-1
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p153 - 2 Jun 2018 Various toxicities: 4 case reports In a retrospective study of 24 patients, four patients [ages and sexes not stated] were described who developed haematological toxicity, ulcer, gastric haemorrhage or duodenal stenosis following treatment with gemcitabine and erlotinib [routes, durations of treatments to reactions onsets and outcomes not stated] for locally advanced pancreatic cancer. The patients with unresectable locally advanced pancreatic cancer started receiving chemoradiotherapy (CRT) with gemcitabine 1000 mg/m on days 1, 8 and 15 and erlotinib 100 mg daily on a 4 week cycle, along with radiotherapy. The patients experienced grade 3 haematological toxicity, grade 2 ulcer, grade 3 gastric haemorrhage and grade 3 duodenal stenosis (one patient each). Author comment: "Grade 3 hematologic toxicity was observed in . . . 1 patient during CRT." "[G]rade 2 ulcer developed in 1 patient". "Grade 3 gastric hemorrhage was observed in 1 patient who received 50.4 Gy and grade 3 duodenal stenosis in 1 patient who received 55.8 Gy." Kim E, et al. Chemoradiotherapy after gemcitabine plus erlotinib in patients with locally advanced pancreatic cancer. Journal of B. U. ON: Official Journal of the Balkan Union of Oncology 22: 1046-1052, No. 4, Jul-Aug

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.